171 related articles for article (PubMed ID: 14668694)
1. Bioequivalence of azathioprine products.
Baker DE
Rev Gastroenterol Disord; 2003; 3(4):219-23. PubMed ID: 14668694
[TBL] [Abstract][Full Text] [Related]
2. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
[TBL] [Abstract][Full Text] [Related]
3. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
[TBL] [Abstract][Full Text] [Related]
5. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
6. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD.
Seidman EG
Rev Gastroenterol Disord; 2003; 3 Suppl 1():S30-8. PubMed ID: 12684587
[TBL] [Abstract][Full Text] [Related]
7. TPMT testing before azathioprine therapy?
Drug Ther Bull; 2009 Jan; 47(1):9-12. PubMed ID: 19129430
[TBL] [Abstract][Full Text] [Related]
8. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
[TBL] [Abstract][Full Text] [Related]
9. [Genetic polymorphism and treatment of chronic bowel inflammatory diseases: the example of azathioprine].
Bessard G; Hardy G; Chartier A; Stanke-Labesque F
Therapie; 2004; 59(1):71-5. PubMed ID: 15199672
[TBL] [Abstract][Full Text] [Related]
10. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG
Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564
[TBL] [Abstract][Full Text] [Related]
11. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease.
Winter JW; Gaffney D; Shapiro D; Spooner RJ; Marinaki AM; Sanderson JD; Mills PR
Aliment Pharmacol Ther; 2007 May; 25(9):1069-77. PubMed ID: 17439508
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacogenetic study of thiopurine S-methyltransferase (TPMT) and thiopurine toxicity].
Corominas H; Díaz C; Vázquez G; Baiget M
Rev Esp Enferm Dig; 2002 Oct; 94(10):635-6. PubMed ID: 12647415
[No Abstract] [Full Text] [Related]
13. Should we test TPMT enzyme levels before starting azathioprine?
Richard VS; Al-Ismail D; Salamat A
Hematology; 2007 Aug; 12(4):359-60. PubMed ID: 17654066
[TBL] [Abstract][Full Text] [Related]
14. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
[TBL] [Abstract][Full Text] [Related]
15. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
[TBL] [Abstract][Full Text] [Related]
16. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis.
Heneghan MA; Allan ML; Bornstein JD; Muir AJ; Tendler DA
J Hepatol; 2006 Oct; 45(4):584-91. PubMed ID: 16876902
[TBL] [Abstract][Full Text] [Related]
17. Thiopurine therapy in inflammatory bowel disease.
Ha C; Dassopoulos T
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143
[TBL] [Abstract][Full Text] [Related]
18. Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris.
Firooz A; Ghandi N; Hallaji Z; Chams-Davatchi C; Valikhani M; Karbakhsh Davari M
Arch Dermatol; 2008 Sep; 144(9):1143-7. PubMed ID: 18794458
[TBL] [Abstract][Full Text] [Related]
19. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?
Sanderson J; Ansari A; Marinaki T; Duley J
Ann Clin Biochem; 2004 Jul; 41(Pt 4):294-302. PubMed ID: 15298741
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.
Winter J; Walker A; Shapiro D; Gaffney D; Spooner RJ; Mills PR
Aliment Pharmacol Ther; 2004 Sep; 20(6):593-9. PubMed ID: 15352906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
